Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ATP5E
REST API REST API
Homo sapiens
ATP5E is differentially expressed in 225 experiments: 111 organism parts: hypothalamus, lung, ... (109 more);, 131 disease states: normal, control, ... (129 more);, 64 cell types 328 cell lines 32 compound treatments and 71 other conditions.
Orthologs ATP5E_BOVIN (Bos taurus)   ENSGALG00000007442 (Gallus gallus)   ATP5E_BOVIN (Bos taurus)   Atp5e (Mus musculus)   Atp5e (Rattus norvegicus)   ATP5EP2 (Danio rerio)   ENSCAFG00000012218 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term mitochondrial proton-transporting ATP synthase complex, ion transport, membrane, ATPase activity, respiratory electron transport chain, mitochondrial matrix, mitochondrial proton-transporting ATP synthase complex, catalytic core F(1), mitochondrial ATP synthesis coupled proton transport, proton-transporting ATPase activity, rotational mechanism, proton transport, hydrolase activity, ATP synthesis coupled proton transport, hydrogen ion transporting ATP synthase activity, rotational mechanism, mitochondrion, ATP catabolic process, transmembrane transporter activity
InterPro Term ATPase_F1-cplx_esu_mt
UniProt Accession P56381
Gene-Disease Assocation MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 3;
Search EB-eye ENSG00000124172
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-MEXP-1251, E-MTAB-24, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (32 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-3529, E-GEOD-5823, E-GEOD-20081
BT-474
2
E-GEOD-5823, E-GEOD-3529
BT474
2
E-MEXP-440, E-MTAB-62
K562
2
E-GEOD-24147, E-MTAB-37
MDA-MB-231
2
E-GEOD-5823, E-TABM-420
MDA468
2
E-MEXP-440, E-MTAB-62
322 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-13909, E-GEOD-13987, ... (35 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
1
2
E-TABM-145, E-TABM-130
cardiac myocyte
1
E-AFMX-5
vascular smooth muscle cell
1
E-TABM-130
PBMCs
1
E-GEOD-20677
ovarian cancer
1
E-GEOD-21154
58 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1615, E-GEOD-6872, E-MEXP-2069, E-TABM-15, ... (48 experiments)

Factor Value U/D Experiments
melanoma
2
E-MTAB-62, E-MTAB-37
squamous cell carcinoma
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
control
1
2
E-GEOD-21912, E-GEOD-16363, E-GEOD-16728
rhabdomyosarcoma
1
E-MTAB-37
lymphoma
1
E-MTAB-62
125 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-6907, E-GEOD-5824, E-TABM-868, E-GEOD-6462, ... (19 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
interleukin-24 (Homo sapiens)
1
E-GEOD-7216
NaOH
1
1
E-MEXP-2590
ethanol
1
E-GEOD-3113
estradiol
1
E-GEOD-20081
26 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
143.2
1
1
E-TABM-325
54.53
1
E-TABM-325
112.03
1
1
E-TABM-325
116.59
1
1
E-TABM-325
117.26
1
1
E-TABM-325
126.1
1
1
E-TABM-325
5 more value(s).


Age at diagnosis
studied in E-GEOD-3494, E-GEOD-4922

Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-7788, E-GEOD-3325, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-3494, E-MEXP-421, E-GEOD-22593, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-TABM-127, E-GEOD-20540, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-5764, E-TABM-740, E-GEOD-9593, ... (28 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-MEXP-1403

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-13818, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-22541, E-GEOD-6532, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.345 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM